Exelixis
EXEL
#1619
Rank
ยฃ8.16 B
Marketcap
ยฃ29.18
Share price
-0.03%
Change (1 day)
55.58%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): ยฃ0.53 Billion

According to Exelixis's latest financial reports the company's current earnings are ยฃ2.16 Billion. , an increase over its 2023 earnings that were of ยฃ0.19 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 ยฃ0.52 B164.69%
2023 ยฃ0.19 B9.89%
2022 ยฃ0.18 B-20.33%
2021 ยฃ0.22 B124.82%
2020 ยฃ0.10 B-67.14%
2019 ยฃ0.30 B-11.94%
2018 ยฃ0.34 B185.09%
2017 ยฃ0.12 B-325.82%
2016 -ยฃ54.34 Million-58.12%
2015 -ยฃ0.13 Billion-37.61%
2014 -ยฃ0.21 Billion9.75%
2013 -ยฃ0.19 Billion65.96%
2012 -ยฃ0.12 Billion-291.63%
2011 ยฃ59.56 M-195.59%
2010 -ยฃ62.32 Million-42.17%
2009 -ยฃ0.11 Billion-18.98%
2008 -ยฃ0.14 Billion-6.99%
2007 -ยฃ0.15 Billion46.3%
2006 -ยฃ97.76 Million33.25%
2005 -ยฃ73.36 Million-30.92%
2004 -ยฃ0.11 Billion44.29%
2003 -ยฃ73.6 Million12.86%
2002 -ยฃ65.22 Million22.79%
2001 -ยฃ53.11 Million60.14%
2000 -ยฃ33.17 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
ยฃ3.40 B 544.70%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ6.14 B 1,065.14%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ16.40 B 3,011.17%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ6.49 Billion-1,329.24%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ3.56 B 576.16%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ13.49 B 2,458.83%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ8.59 B 1,530.33%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ34.67 Million-106.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ22.47 Million-104.26%๐Ÿ‡บ๐Ÿ‡ธ USA